rdf-syntax-grammar
mods:
  schema location: http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
  title info:
    title: Pharmacology & Therapeutics of Constitutively Active Receptors
  name:
    name part: Tao, Ya-Xiong.
  type of resource: text
  genre: Electronic books.
  origin info:
    place:
      place term: onc
    place:
      place term: Burlington
    publisher: Elsevier Science
    date issued: 2014
    issuance: monographic
  language:
    language term: eng
  physical description:
    form: remote
    extent: 1 online resource (434 pages)
  abstract: Volume 70 of Advances in Pharmacology presents the pharmacology and therapeutics of constitutively active receptors. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists, and biochemists alike. Advances in Pharmacology provides a rich collection of reviews on timely topics. The series places emphasis on the molecular bases of drug action, both applied and experimental. Contributions from the best authors in the fieldAn essential resource for pharmacologists, immu.
  table of contents: Front Cover; Pharmacology & Therapeutics of Constitutively Active Receptors; Copyright; Contents; Preface; Contributors; Chapter One: Constitutively Active Rhodopsin and Retinal Disease; 1. Introduction; 2. Rhodopsin Activity; 2.1. Physiology of rhodopsin activity; 2.2. Molecular switches that lock rhodopsin in an inactive state; 3. Constitutive Activity in Rhodopsin that Causes Disease; 3.1. Leber congenital amaurosis and vitamin A deficiency; 3.1.1. Opsin: Active apoprotein; 3.2. Congenital night blindness; 3.2.1. G90D: Active dark state; 3.2.2. T94I, A292E, and A295V: Active dark state.
  table of contents: 3.3. Retinitis pigmentosa3.3.1. S186W and D190N: Thermal activation; 3.3.2. G90V: Active dark state and thermal activation; 3.3.3. K296E: Active apoprotein and stable arrestin interactions; 4. How Constitutive Activity Can Cause Different Phenotypes; 4.1. Different levels of activity as an underlying cause of different phenotypes; 4.2. Do all constitutively active mutants adopt the same active-state conformation?; 5. Conclusion; Conflict of Interest; Acknowledgments; References; Chapter Two: Constitutive Activity in Gonadotropin Receptors; 1. Introduction.
  table of contents: 2. Naturally Occurring CAMs of the Gonadotropin Receptors2.1. CAMs of the human LHCGR; 2.2. CAMs of the human FSHR; 3. Experimental Models of Gonadotropin Receptor CAMs; 3.1. LHCGR CAMs and LH/hCG overexpressing mice; 3.2. FSHR CAMs and FSHR overexpressing mice; 4. Molecular Basis of Constitutive Activity in Gonadotropin Receptors; 4.1. Mechanism of ligand-induced activation in gonadotropin receptors; 4.2. Mechanisms leading to constitutive activity of gonadotropin receptors; 5. Design of New Molecules for Controlling the Activity of Constitutively Active Gonadotropin Receptors; 6. Conclusion.
  table of contents: Conflict of InterestAcknowledgments; References; Chapter Three: Constitutive Activities in the Thyrotropin Receptor: Regulation and Significance; 1. Introduction; 2. Constitutive Activity in the Thyrotropin Receptor; 2.1. Properties related to Gs-mediated basal signaling activity; 2.1.1. Structural determinants involved in regulation of basal signaling activity; 2.1.2. Physiological aspects of basal signaling; 2.2. Modulation of constitutive signaling activity; 2.2.1. Constitutive signaling activity induced by mutations; 2.2.2. Silencing of constitutive activity.
  table of contents: 2.2.2.1. Constitutive inactivation by mutations2.2.2.2. Small-molecule ligands with inverse agonistic properties; 2.2.2.3. Antibodies with inverse agonistic properties; 3. Conclusion; Conflict of Interest; Acknowledgments; References; Chapter Four: Constitutive Activity in Cannabinoid Receptors; 1. Introduction; 2. Challenges in Proving Constitutive Receptor Activity; 2.1. Demonstrating constitutive receptor activity requires the use of agonist, inverse agonist, and neutral antagonist; 2.2. Constitutive active receptor versus constitutive agonist tone.
  note: edited by Ya-Xiong Tao.
  note: 2.3. Design issues in in vitro cell-based assay.
  subject:
    topic: Clinical pharmacology
  subject:
    topic: MEDICAL
    topic: Pharmacology
  subject:
    topic: Clinical pharmacology
  classification: RM301.28
  classification: 615.1
  related item:
    title info:
      title: Pharmacology & Therapeutics of Constitutively Active Receptors
    name:
      name part: Tao, Ya-Xiong.
    origin info:
      publisher: Burlington : Elsevier Science, 2014
  related item:
    title info:
      title: Advances in pharmacology ; v. 70
  identifier: 9780124172067
  identifier: 0124172067
  identifier: 9780124171978
  identifier: https://www.sciencedirect.com/science/bookseries/10543589/70
  record info:
    record content source: EBLCP
    record creation date: 140628
    record change date: 20180501122019.0
    record identifier: ocn881887427
    language of cataloging:
      language term: eng